---
schema_version: "secwatch.filing_event.v1"
accession: "0001628280-26-011395"
form_type: "8-K"
ticker: "CRL"
cik: "0001100682"
company_name: "CHARLES RIVER LABORATORIES INTERNATIONAL, INC."
filed_at: "2026-02-25T23:59:59+00:00"
generated_at: "2026-05-16T00:05:32.123654+00:00"
event_type: "other_material"
sentiment: "positive"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# Charles River to divest CDMO/Cell Solutions and European Discovery assets; updates 2026 guidance

## Summary
- Definitive agreement to sell CDMO and Cell Solutions to GI Partners for future performance-based payments; $143M 2025 revenue.
- Agreement to sell certain European Discovery Services assets to IQVIA for ~$145M cash plus up to $10M contingent; $144M 2025 revenue.
- Updated 2026 guidance: reported revenue growth (5.0)% to (3.5)%; non-GAAP EPS $10.80-$11.30.
- Divestitures expected to reduce 2026 reported revenue by >$200M, but add at least 100 bps non-GAAP operating margin and ~$0.10 EPS.
- Both transactions expected to close in Q2 2026, subject to customary closing conditions.

## SEC filing metadata
- accession: 0001628280-26-011395
- form_type: 8-K
- ticker: CRL
- cik: 0001100682
- company_name: CHARLES RIVER LABORATORIES INTERNATIONAL, INC.
- filed_at: 2026-02-25T23:59:59+00:00
- event_type: other_material
- sentiment: positive
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 7.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1100682/000162828026011395/0001628280-26-011395-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1100682/000162828026011395/crl-20260225.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001628280-26-011395
- JSON: https://secwatch.observer/filing/0001628280-26-011395.json
- Plain text: https://secwatch.observer/filing/0001628280-26-011395.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.